<DOC>
	<DOCNO>NCT01822249</DOCNO>
	<brief_summary>Rett syndrome severe neurodevelopmental disorder primarily affect female child . Rett syndrome characterize significant elevation blood marker oxidative stress . EPI-743 novel therapeutic demonstrate efficacy safety treatment disorder characterize oxidative stress . The purpose study examine safety efficacy EPI-743 population child Rett syndrome .</brief_summary>
	<brief_title>Phase 2 Study EPI-743 Treatment Rett Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Rett Syndrome</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Diagnosis Rett syndrome disease stage 12 Abnormality least two disease biomarker level Confirmed MeCP2 mutation Patient patient 's guardian able consent comply protocol requirement Abstention use Coenzyme Q10 , vitamin E Idebenone two week prior enrollment study Any condition , opinion investigator could compromise subject 's safety adherence treatment EPI743 . Clinically significant allergy hypersensitivity EPI743 excipients EPI743 ( eg. , sesame oil ) . Clinically significant allergy hypersensitivity Vitamin E Lack confirmation MeCP2 mutation Clinical history bleed abnormal baseline PT/PTT Diagnosis concurrent inborn error metabolism Hepatic insufficiency LFTs great 3 time upper limit normal Renal insufficiency require dialysis End stage cardiac failure Fat malabsorption syndrome preclude drug absorption</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Rett syndrome</keyword>
	<keyword>EPI-743</keyword>
	<keyword>Edison</keyword>
</DOC>